AGP
Artia Global Partners Portfolio holdings
AUM
$389M
This Quarter Return
+42.93%
1 Year Return
+34.68%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$408M
AUM Growth
+$408M
(+61%)
Cap. Flow
+$82.4M
Cap. Flow
% of AUM
20.2%
Top 10 Holdings %
Top 10 Hldgs %
79.23%
Holding
52
New
23
Increased
12
Reduced
1
Closed
3
Top Buys
| 1 |
Vertex Pharmaceuticals
VRTX
|
$12.1M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$11.7M |
| 3 |
Merck
MRK
|
$6.6M |
| 4 |
Disc Medicine
IRON
|
$5.42M |
| 5 |
Viking Therapeutics
VKTX
|
$4.1M |
Top Sells
| 1 |
Novo Nordisk
NVO
|
$3.82M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$2.79M |
| 3 |
Waters Corp
WAT
|
$937K |
| 4 |
Tyra Biosciences
TYRA
|
$142K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Novo Nordisk
NVO
$251B
| $88.8M | 17.85% |
691,743
-29,764
| -4% | -$3.82M |
|
2
Eli Lilly
LLY
$657B
| $72M | 14.48% |
92,593
| – | – |
|
|
3
Merck
MRK
$210B
| $50M | 10.06% |
379,200
+50,000
| +15% | +$6.6M |
|
|
4
Viking Therapeutics
VKTX
$3.04B
| $35.6M | 7.15% |
433,580
+50,000
| +13% | +$4.1M |
|
5
AbbVie
ABBV
$372B
| $16.5M | 3.32% |
90,821
| – | – |
|
|
ITCI
6
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $14.5M | 2.92% |
210,096
+168,496
| +405% | +$11.7M |
|
7
argenx
ARGX
$43.6B
| $13.5M | 2.71% |
34,238
| – | – |
|
8
AstraZeneca
AZN
$248B
| $12.9M | 2.6% |
190,752
| – | – |
|
|
9
Vertex Pharmaceuticals
VRTX
$100B
| $12.1M | 2.43% |
+28,900
| New | +$12.1M |
|
10
Axsome Therapeutics
AXSM
$6.05B
| $7.01M | 1.41% |
87,848
| – | – |
|
11
Ocular Therapeutix
OCUL
$2.12B
| $6.59M | 1.33% |
724,685
+284,685
| +65% | +$2.59M |
|
12
Cytokinetics
CYTK
$4.23B
| $6.28M | 1.26% |
89,525
+57,412
| +179% | +$4.03M |
|
13
Neurocrine Biosciences
NBIX
$13.8B
| $6.21M | 1.25% |
45,000
| – | – |
|
|
14
Disc Medicine
IRON
$2.07B
| $5.42M | 1.09% |
+87,040
| New | +$5.42M |
|
15
Vaxcyte
PCVX
$4B
| $5.21M | 1.05% |
76,255
+37,700
| +98% | +$2.58M |
|
16
Apogee Therapeutics
APGE
$2.17B
| $4.09M | 0.82% |
61,590
+51,209
| +493% | +$3.4M |
|
17
Crinetics Pharmaceuticals
CRNX
$2.92B
| $4.01M | 0.81% |
+85,765
| New | +$4.01M |
|
18
Protagonist Therapeutics
PTGX
$3.67B
| $3.6M | 0.72% |
124,440
+12,100
| +11% | +$350K |
|
19
Dyne Therapeutics
DYN
$1.92B
| $3.39M | 0.68% |
+119,488
| New | +$3.39M |
|
20
Insmed
INSM
$28.8B
| $3.21M | 0.64% |
118,236
+43,300
| +58% | +$1.17M |
|
|
SWTX
21
DELISTED
SpringWorks Therapeutics
SWTX
| $2.65M | 0.53% |
+53,930
| New | +$2.65M |
|
22
Ascendis Pharma
ASND
$11.8B
| $2.4M | 0.48% |
+15,894
| New | +$2.4M |
|
23
IDEAYA Biosciences
IDYA
$2.15B
| $2.3M | 0.46% |
+52,492
| New | +$2.3M |
|
24
Merus
MRUS
$4.98B
| $2.26M | 0.45% |
+50,171
| New | +$2.26M |
|
|
VRNA
25
Verona Pharma
VRNA
$9.16B
| $2.1M | 0.42% |
130,790
| – | – |
|